

## SEQUENCE LISTING

<110> Cohen, David I.  
<120> Tat-based Tolerogen Compositions and Method of Making and Using Same  
<130> 51311-00001  
<150> 60/553733  
<151> 2004-03-16  
<150> 60/649021  
<151> 2005-01-31  
<150> 10/456865  
<151> 2003-06-06  
<150> 09/636057  
<151> 2000-08-08  
<160> 11  
<170> PatentIn version 3.2  
<210> 1  
<211> 101  
<212> PRT  
<213> Human immunodeficiency virus type 1  
<400> 1

Met Glu Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser  
1               5                                   10                           15

Gln Pro Lys Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe  
20   25                                   30

His Cys Gln Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly  
35   40                                   45

Arg Lys Lys Arg Arg Gln Arg Arg Arg Ala Pro Glu Asp Ser Gln Thr  
50   55                                   60

His Gln Val Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp  
65   70                                   75                                   80

Pro Thr Gly Pro Lys Glu Ser Lys Lys Val Glu Arg Glu Thr Glu  
85   90                                   95

Thr His Pro Val Asp  
100

<210> 2  
<211> 303  
<212> DNA  
<213> Human immunodeficiency virus type 1

<400> 2  
atggagcccg tggaccctcg cctggagccc tggaaaggcacc cgggcagcca gcccaagacc      60

gcctgcacca catgttactg caagaagtgc tgcttccact gccaggtgtg cttcaccaag 120  
 aaggccttgg gcatcagcta cggccgcaag aagcgccggc agcgccgccc ggccccctgag 180  
 gacagccaga cccaccaggt gagccctccc aagcagcccc ctccacagtt ccgcggcgac 240  
 cctaccggtc ccaaggagag caagaagaag gtggagcgcg agaccgagac ccatcccgtc 300  
 gac 303

<210> 3  
 <211> 17  
 <212> PRT  
 <213> Human immunodeficiency virus type 1  
 <400> 3

Pro Val Asp Pro Arg Leu Glu Pro Trp Lys His Pro Gly Ser Gln Pro  
 1 5 10 15

Lys

<210> 4  
 <211> 21  
 <212> PRT  
 <213> Human immunodeficiency virus type 1  
 <400> 4

Pro Cys Asp Trp Pro Leu Thr Pro Asp Pro Trp Val Tyr Ser Gly Ser  
 1 5 10 15  
 Gln Pro Lys Val Pro  
 20

<210> 5  
 <211> 27  
 <212> PRT  
 <213> Simian immunodeficiency virus  
 <400> 5

Pro Leu Arg Glu Gln Glu Asn Ser Leu Glu Ser Ser Asn Glu Arg Ser  
 1 5 10 15  
 Ser Cys Ile Leu Glu Ala Asp Ala Thr Thr Pro  
 20 25

<210> 6  
 <211> 11  
 <212> PRT  
 <213> Human immunodeficiency virus type 1  
 <400> 6

Ser Asn Glu Arg Ser Ser Cys Glu Leu Glu Val  
 1 5 10

<210> 7

<211> 16  
<212> PRT  
<213> Human immunodeficiency virus type 1  
<400> 7

Cys	Thr	Thr	Cys	Tyr	Cys	Lys	Lys	Cys	Cys	Phe	His	Cys	Gln	Val	Cys
1				5				10					15		

<210> 8  
<211> 50  
<212> DNA  
<213> Human immunodeficiency virus type 1  
<400> 8  
ccagtagatc ctagactaga gccctggaag catccaggaa gtcagcctaa 50

<210> 9  
<211> 63  
<212> DNA  
<213> Mus musculus  
<400> 9  
ccatgtgact ggccctgac cccgcacccc tgggtatact ccgggggcca gcccaaagtg 60  
ccc 63

<210> 10  
<211> 33  
<212> DNA  
<213> Simian immunodeficiency virus  
<400> 10  
agcaacgagc ggagttcctg cgagtttagag gtg 33

<210> 11  
<211> 98  
<212> PRT  
<213> Artificial  
<220>  
<223> Modified immunostimulatory Tat  
<400> 11

Met	Glu	Pro	Ser	Asn	Glu	Arg	Ser	Ser	Cys	Glu	Leu	Glu	Val	Pro	Lys
1				5					10				15		

Thr Ala Cys Thr Thr Cys Tyr Cys Lys Lys Cys Cys Phe His Cys Gln  
20 25 30

Val Cys Phe Thr Lys Lys Ala Leu Gly Ile Ser Tyr Gly Arg Lys Lys  
35 40 45

Arg Arg Gln Arg Arg Arg Ala Pro Glu Asp Ser Gln Thr His Gln Val  
50 55 60

Ser Pro Pro Lys Gln Pro Ala Pro Gln Phe Arg Gly Asp Pro Thr Gly  
65 70 75 80

Pro Lys Glu Ser Lys Lys Lys Val Glu Arg Glu Thr Glu Thr His Pro  
85 90 95

Val Asp